This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
PSMAddition Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
Prostate Cancer Daily
June 23, 2026
Videos
Peer-to-Peer Clinical Conversations
Comparing Cognitive Change on Enzalutamide and Darolutamide in the ARACOG Trial - Alicia Morgans
Alicia Morgans
Alicia Morgans discusses ARACOG, a randomized trial comparing cognitive outcomes between darolutamide and enzalutamide in advanced prostate cancer.
View
Navigating Treatment Decisions in Castration-Resistant Prostate Cancer - Karim Fizazi
Karim Fizazi
Karim Fizazi discusses mCRPC treatment sequencing, organizing patients into three clinical buckets.
View
Beyond the Abstracts
Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study - Beyond the Abstract
European Registry of Next Generation Imaging in Advanced Prostate Cancer (RING): Protocol for an International, Prospective Registry Study - Beyond the Abstract
Conference Coverage
ASCO 2026: First-Line Metastatic Castration-Resistant Prostate Cancer: One Size Doesn't Fit All
ASCO 2026: How to Better Personalize Treatment with 177Lu-PSMA-617
SNMMI 2026: Survival in Veterans with Metastatic Hormone Sensitive Prostate Cancer Based on PSMA PET/CT Imaging
SNMMI 2026: First in Human CD46-Targeted ImmunoPET Imaging with 89Zr-DFO-YS5 in mCRPC
AUA 2026: Duration of Treatment Suspension Among All Randomized Patients in EMBARK
Articles
Editor Selected Abstracts and Commentaries
Prostate Cancer
Current state of the art of new prostate MRI technologies and potential future developments.
Investigation of Potential Splenic Metastasis on Prostate-Specific Membrane Antigen (PSMA) Imaging in High-Risk Prostate Cancer: A Role for MRI?
Surgical Complications in a large series of Retzius-sparing robot-assisted radical prostatectomy: impact of surgical experience and technical modifications (1016 cases).
Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models.
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.
A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound.
Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2026 Digital Science Press, LLC
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
